Search Videos and More
Video
Wenxin (Vincent) Xu, MD presents a potential biomarker (KIM-1)
Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214.
Video
Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan
Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
News
Early Cancer Detection Studies for High-Risk People
A blood test can now detect the presence of 50 different cancers — most of which do not have any other means of screening.
News
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
A Year of Advances in Genitourinary Cancer
Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.
News
Study of Inherited Prostate Cancer Genetics in Africa Highlights Importance of Research
The genetic landscape of prostate cancer susceptibility in Africa is, like the continent itself, a picture of sweeping diversity, the largest study of the phenomenon concludes.
News
Prostate Cancer Vaccines: What’s the Latest?
Like all vaccines, prostate cancer vaccines work by stimulating the body’s immune system. Unlike vaccines for the flu, COVID-19 and other infections, which protect against disease, prostate cancer vaccines are a form of treatment.?
News
Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer
Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor – Results of the Phase 3 TiNivo-2 Study
Symposium
ESMO Congress 2024
Learn more about prostate, bladder and kidney cancer studies led by Dana-Farber presented at ESMO Congress 2024.
News
Comprehensive Cancer Research from Dana-Farber Leads ESMO Congress 2024
Innovations in breast cancer, targeted therapies, antibody drug conjugates, and kidney cancer
Video
Kidney Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2024.
Video
Bladder Cancer Highlights presented by Michael Serzan, MD
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2024.